PAVmed (PAVM) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Matt Riley - Director - Investor RelationsLishan Aklog - Chairman and CEODennis McGrath - President & CFO Conference Call Participants Jeremy Pearlman - Equity AnalystEdward Woo - Director of Research & Senior Analyst Operator Good morning and welcome to the PAVmed First Quarter twenty twenty five Business Update Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a que ...

Mink Therapeutics (INKT) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Zack Armen - Head of IR & Corporate DevelopmentJennifer Buell - President and CEOChristine Klaskin - CFOThiago Favano - Senior Director, Portfolio Operations Conference Call Participants Emily Bodnar - Biotech Equity Research AnalystMatthew Phipps - Equity Research Analyst Operator Thank you for standing by. My name is Roselle, and I will be your conference operator today. At this time, I would like to welcome every ...

EDAP TMS (EDAP) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants John Fraunces - DirectorRyan Rhodes - CEO & DirectorKen Mobeck - Chief Financial OfficerSean Lee - VP - Equity Research Conference Call Participants Michael Sarcone - Analyst Operator Day. I would like to welcome everyone to EDAP TMS First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer se ...

Ondas (ONDS) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Eric Brock - Chairman, CEO & PresidentNeil Laird - Interim CFO, Treasurer & SecretaryMarkus Nottelmann - CEO - Ondas NetworksOshri Lugassy - Co-CEO - Ondas Autonomous SystemsMax Michaelis - Equity Research Associate Conference Call Participants Glenn Mattson - AnalystMatthew Galinko - SVP & Senior Research AnalystMike Latimore - Managing Director & Senior Research Analyst Operator Welcome to the Ondus Holdings Inc. First Quarte ...

REE Automotive (REE) Q4 2024 Earnings Call May 15, 2025 08:30 AM ET Company Participants Dana Rubinstein - Chief Strategy OfficerDaniel Barel - Co-Founder and CEOHai Aviv - CFO Conference Call Participants C.K. Poe Fratt - MD - Equity Research & Senior Transportation Analyst Operator Good day, and thank you for standing by. Welcome to the RE Automotive's Fourth Quarter and Full Year twenty twenty four Financial Results Conference Call. At this time, all participants are in listen only mode. After the speake ...

Invivyd (IVVD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Katie Falzone - SVP - FinanceMarc Elia - Chairperson of the BoardTimothy Lee - Chief Commercial OfficerRobert Allen - Chief Scientific OfficerMark Wingertzahn - Senior Vice President of Clinical Development & Medical AffairsWilliam Duke - Chief Financial OfficerKyle Yang - Senior AssociateLuis Santos - Senior Equity Research Associate, Healthcare & Biotechnology Operator Thank you for standing by, and welcome to Nvivit's Firs ...

Lazydays (GORV) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Jeff Needles - CFORon Fleming - Interim CEOAmber Dillard - COO Operator and welcome to the Lazydays RV Holdings First Quarter twenty twenty five Conference Call. At this time, all participants are on a listen only mode. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Mr. Jeff Needles, Chief Financial Officer. Thank you. Please go ahead. Jeff Needles Thank you, operator, and welc ...

NICE (NICE) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Welcome to the NICE Conference Call discussing First Quarter twenty twenty five Results, and thank you all for holding. All participants are at present in a listen only mode. Following management's formal presentation, instructions will be given for the question and answer session. As a reminder, this conference is being recorded, 05/15/2025. I would now like to turn this call over to Mr. Marty Cohen, VP of Investor Relations at NICE. Pleas ...

Financial Data and Key Metrics Changes - The company reported a net income of $18.6 million for the first quarter, resulting in a positive primary EPS of $1.28 and a positive diluted EPS of $0.34 [23][24]. - A significant liability reduction of approximately $25 million was achieved, primarily from a reduction in convertible notes and accrued expenses [19][20]. - The company ended the quarter with $40 million in pro forma cash, extending its runway well into 2026 [11]. Business Line Data and Key Metrics Changes - Lucid, the company's diagnostic subsidiary, reported revenue of $800,000 with a test volume of 3,034, meeting the target range [10]. - Verus has restarted the development of a key implantable physiologic monitor after securing financing [12][14]. - The incubator PMX is focused on advancing technologies, particularly the PortIO device, with ongoing discussions with strategic partners [8][14]. Market Data and Key Metrics Changes - The company is seeing momentum in new sales channels, particularly in concierge medicine and employer market contracts, which are expected to impact revenue in the second half of the year [11][12]. - The company is awaiting a response from the MolDX program regarding Medicare coverage for EsoGuard, which is anticipated to be imminent [12]. Company Strategy and Development Direction - The company aims to diversify into the biopharma space, leveraging its infrastructure and management services model to capitalize on early-stage assets in oncology and cardiometabolic areas [9][39]. - The strategic focus includes expanding partnerships and exploring new assets that fit within the shared services model [10][39]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning and ability to execute its strategic vision, highlighting the potential value creation from Lucid and Verus [51][52]. - The company is optimistic about leveraging its model and infrastructure to pursue significant opportunities in the near future [52][53]. Other Important Information - The company has deconsolidated Lucid from its financial statements, which will affect year-over-year comparisons in the upcoming quarters [16][22]. - PAVmed remains the largest shareholder of Lucid, holding approximately 29% of the common shares outstanding [20]. Q&A Session Summary Question: Feedback from the pilot program - Management received excellent feedback from the pilot program, with all pre-specified performance metrics met and enthusiasm from academic medical centers [31][32]. Question: Exclusive rights to the platform - There are local rights for advancing the platform, but no exclusivity that limits broader commercialization efforts [34][35]. Question: Rationale for expanding into biopharma - The company is leveraging its adjusted corporate structure and management services to explore opportunities in biopharma, particularly in early-stage assets that require clinical research [39][40]. Question: Impact of market volatility on capital raising - Management indicated that market volatility has not significantly affected their ability to raise capital, with successful financing in the first quarter [47][48].

Financial Data and Key Metrics Changes - The company improved its liquidity to $72 million at the end of 2024, including an $18 million credit facility, following two successful securities offerings that raised approximately $60 million in gross proceeds [12] - The GAAP net loss for the full year was $111.8 million, a slight improvement from $114.2 million in 2023, primarily due to lower engineering and R&D expenses [13] - On a non-GAAP basis, the net loss improved to $70.3 million from $98.3 million in 2023, driven by reductions in engineering and R&D expenses [14] Business Line Data and Key Metrics Changes - The company achieved significant milestones in technology, including the first federal motor vehicle safety standard certification for a full by-wire vehicle in the US and the completion of the first autonomous drive on an active runway with Airbus [5][8] - The launch of ReAI Cloud in collaboration with Geotab opened new software revenue opportunities, indicating a shift towards a software-driven business model [5] Market Data and Key Metrics Changes - The company reported close to $1 billion in reservations, which includes binding orders and capacity reservations, indicating strong demand for its technology despite the temporary pause in production [34] - The current US tariffs and trade policies have significantly impacted the supply chain, affecting the company's ability to execute its original production plans [7][8] Company Strategy and Development Direction - The company is focusing on a software-first approach, transitioning towards a subscription-based revenue model and licensing its technology to OEMs and technology companies [10][20] - A strategic decision was made to temporarily pause production to address uncertainties in the macroeconomic environment and tariffs, while prioritizing software development [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology and its ability to adapt to market conditions, emphasizing the importance of preserving cash for future flexibility [21] - The company remains optimistic about the demand for its software-defined vehicle technology, which is seen as a cornerstone for future mobility [9][22] Other Important Information - The company plans to significantly reduce monthly operational expenses, targeting a reduction from $5-6 million to $3-4 million by the end of the year [30] - There is substantial doubt about the company's ability to continue as a going concern for the next twelve months, prompting plans for cost reductions and restructuring [17] Q&A Session Summary Question: Can you talk about the conversion of the MOU to a definitive agreement? - Management indicated that there is currently no change in the timeline for the MOU and that payments have already started being received for services delivered [27][28] Question: What is the actual cash balance at the end of the quarter excluding the credit facility? - The cash balance was reported at $61 million excluding the credit facility [29] Question: Can you discuss the cash burn and headcount at the end of the quarter? - The anticipated operating expenses are expected to be between $5-6 million a month, with plans to reduce this to $3-4 million by year-end [30][31] Question: Have there been any cancellations in reservations due to the production pause? - Management noted that customer interest in the product has increased, and they believe there is strong demand for their technology despite the production pause [34]